149 related articles for article (PubMed ID: 37574332)
1. Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenström Macroglobulinemia.
Bustoros M; Gribbin C; Castillo JJ; Furman R
Hematol Oncol Clin North Am; 2023 Aug; 37(4S):e1-e13. PubMed ID: 37574332
[TBL] [Abstract][Full Text] [Related]
2. Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.
Drandi D; Decruyenaere P; Ferrante M; Offner F; Vandesompele J; Ferrero S
Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35454017
[TBL] [Abstract][Full Text] [Related]
3. Progression from Monoclonal gammopathy of undetermined significance of the immunoglobulin M class (IgM-MGUS) to Waldenstrom Macroglobulinemia is associated with an alteration in lipid metabolism.
Jalali S; Shi J; Ahsan N; Wellik L; Serres M; Buko A; Paludo J; Kim H; Tang X; Yang ZZ; Novak A; Kyle R; Ansell S
Redox Biol; 2021 May; 41():101927. PubMed ID: 33690107
[TBL] [Abstract][Full Text] [Related]
4. Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia.
Tahri S; Mouhieddine TH; Redd R; Lampe L; Nilsson KI; El-Khoury H; Su NK; Nassar AH; Adib E; Bindra G; Abou Alaiwi S; Trippa L; Steensma DP; Castillo JJ; Treon SP; Ghobrial IM; Sperling AS
Blood Adv; 2022 Apr; 6(7):2230-2235. PubMed ID: 34847227
[TBL] [Abstract][Full Text] [Related]
5. The cellular origin and malignant transformation of Waldenström macroglobulinemia.
Paiva B; Corchete LA; Vidriales MB; García-Sanz R; Perez JJ; Aires-Mejia I; Sanchez ML; Barcena P; Alignani D; Jimenez C; Sarasquete ME; Mateos MV; Ocio EM; Puig N; Escalante F; Hernández J; Cuello R; García de Coca A; Sierra M; Montes MC; González-López TJ; Galende J; Bárez A; Alonso J; Pardal E; Orfao A; Gutierrez NC; San Miguel JF
Blood; 2015 Apr; 125(15):2370-80. PubMed ID: 25655603
[TBL] [Abstract][Full Text] [Related]
6. Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors.
Varettoni M; Zibellini S; Capello D; Arcaini L; Rossi D; Pascutto C; Rattotti S; Mangiacavalli S; Pochintesta L; Gotti M; Gaidano G; Cazzola M
Leuk Lymphoma; 2013 Nov; 54(11):2485-9. PubMed ID: 23442064
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.
Tedeschi A; Conticello C; Rizzi R; Benevolo G; Laurenti L; Petrucci MT; Zaja F; Varettoni M
Hematol Oncol; 2019 Apr; 37(2):117-128. PubMed ID: 30192023
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
Mailankody S; Landgren O
Best Pract Res Clin Haematol; 2016 Jun; 29(2):187-193. PubMed ID: 27825465
[TBL] [Abstract][Full Text] [Related]
9. Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy.
Moreno DF; Pereira A; Tovar N; Cibeira MT; Magnano L; Rozman M; López-Guerra M; Colomer D; Martín-Antonio B; Jiménez-Segura R; Isola I; Rodríguez-Lobato LG; Oliver-Caldés A; Mena MP; Rosiñol L; Bladé J; Fernández de Larrea C
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922804
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia.
Kyle RA; Therneau TM; Dispenzieri A; Kumar S; Benson JT; Larson DR; Melton LJ; Rajkumar SV
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):184-6. PubMed ID: 23490989
[TBL] [Abstract][Full Text] [Related]
11. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.
Varettoni M; Zibellini S; Defrancesco I; Ferretti VV; Rizzo E; Malcovati L; Gallì A; Porta MGD; Boveri E; Arcaini L; Candido C; Paulli M; Cazzola M
Haematologica; 2017 Dec; 102(12):2077-2085. PubMed ID: 28983055
[TBL] [Abstract][Full Text] [Related]
12. Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification.
Paiva B; Montes MC; García-Sanz R; Ocio EM; Alonso J; de Las Heras N; Escalante F; Cuello R; de Coca AG; Galende J; Hernández J; Sierra M; Martin A; Pardal E; Bárez A; Alonso J; Suarez L; González-López TJ; Perez JJ; Orfao A; Vidríales MB; San Miguel JF
Leukemia; 2014 Jan; 28(1):166-73. PubMed ID: 23604227
[TBL] [Abstract][Full Text] [Related]
13. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
Varettoni M; Zibellini S; Boveri E; Klersy C; Candido C; Rattotti S; Ferretti VV; Defrancesco I; Mangiacavalli S; Nizzoli ME; Flospergher E; Zerbi C; Bergamini F; Benvenuti P; Brociner M; Merati G; Paulli M; Arcaini L
Br J Haematol; 2019 Nov; 187(4):441-446. PubMed ID: 31276195
[TBL] [Abstract][Full Text] [Related]
14. Survival in monoclonal gammopathy of undetermined significance and Waldenström macroglobulinemia.
Kristinsson SY; Björkholm M; Landgren O
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):187-90. PubMed ID: 23490991
[TBL] [Abstract][Full Text] [Related]
15. Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells.
Trojani A; Di Camillo B; Bossi LE; Leuzzi L; Greco A; Tedeschi A; Frustaci AM; Deodato M; Zamprogna G; Beghini A; Cairoli R
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921415
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
[TBL] [Abstract][Full Text] [Related]
17. Serum markers in the differential diagnosis of Waldenstrom macroglobulinemia and other IgM monoclonal gammopathies.
Zou H; Yang R; Liao ZX; Qin TD; Chen P; Zhang BY; Cao YP; Huang HF
J Clin Lab Anal; 2019 Mar; 33(3):e22827. PubMed ID: 30485557
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
19. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
20. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.
Xu L; Hunter ZR; Yang G; Zhou Y; Cao Y; Liu X; Morra E; Trojani A; Greco A; Arcaini L; Varettoni M; Brown JR; Tai YT; Anderson KC; Munshi NC; Patterson CJ; Manning RJ; Tripsas CK; Lindeman NI; Treon SP
Blood; 2013 Mar; 121(11):2051-8. PubMed ID: 23321251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
